Cytarabine as a Chemotherapeutic Agent for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.
Partial remission or better was observed in 85% of evaluable patients who received pomalidomide, cyclophosphamide, and dexamethasone.
PET-CT Scans May Be Useful in Predicting Prognosis in Patients With Newly Diagnosed Multiple Myeloma
PET-CT scans can reveal abnormalities such as bony lesions and extramedullary disease in patients with multiple myeloma.
First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.
An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.
Drug coverage status influenced the treatments that were selected for Medicare beneficiaries with myeloma and, consequently, their overall survival.
Previous studies have suggested that light therapy may improve depression by synchronizing patients' circadian rhythm.
Evidence supporting the overall superiority of a single regimen in the maintenance setting in newly diagnosed multiple myeloma is lacking.
The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.
A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.